Global HDAC (histone deacetylase) Inhibitors Market 2019-2023
SKU ID : TNV-14098769 | Publishing Date : 29-Mar-2019 | No. of pages : 117
Detailed TOC of Global HDAC (histone deacetylase) Inhibitors Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: CUSTOMER LANDSCAPE
PART 07: MARKET SEGMENTATION BY ROA
• Market segmentation by RoA
• Comparison by RoA
• Oral HDAC inhibitors - Market size and forecast 2018-2023
• Parenteral HDAC inhibitors - Market size and forecast 2018-2023
• Market opportunity by RoA
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• CELGENE CORPORATION
• Merck & Co., Inc.
• Novartis AG
• Shenzhen Chipscreen Biosciences Co., Ltd.
• Spectrum Pharmaceuticals, Inc.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Customer landscape
Exhibit 18: RoA - Market share 2018-2023 (%)
Exhibit 19: Comparison by RoA
Exhibit 20: Oral HDAC inhibitors - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Oral HDAC inhibitors: Pipeline overview
Exhibit 22: Oral HDAC inhibitors - Year-over-year growth 2019-2023 (%)
Exhibit 23: Parenteral HDAC inhibitors - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Parenteral HDAC inhibitors - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by RoA
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Prevalence of top 5 cancers newly reported in US 2015
Exhibit 43: Pipeline of combination therapies - Syndax
Exhibit 44: Treatment costs of HDAC inhibitors
Exhibit 45: Alternative treatment options for oncology conditions
Exhibit 46: Side effects of HDAC
Exhibit 47: Impact of drivers and challenges
Exhibit 48: Some strategic alliances in global HDAC inhibitors market
Exhibit 49: drugs with respect to their cancer indications and expanded indications
Exhibit 50: Vendor landscape
Exhibit 51: Landscape disruption
Exhibit 52: Vendors covered
Exhibit 53: Vendor classification
Exhibit 54: Market positioning of vendors
Exhibit 55: CELGENE CORPORATION - Vendor overview
Exhibit 56: CELGENE CORPORATION - Business segments
Exhibit 57: CELGENE CORPORATION - Organizational developments
Exhibit 58: CELGENE CORPORATION - Geographic focus
Exhibit 59: CELGENE CORPORATION - Key offerings
Exhibit 60: CELGENE CORPORATION - Key customers
Exhibit 61: Merck & Co., Inc. - Vendor overview
Exhibit 62: Merck & Co., Inc. - Business segments
Exhibit 63: Merck & Co., Inc. - Organizational developments
Exhibit 64: Merck & Co., Inc. - Geographic focus
Exhibit 65: Merck & Co., Inc. - Segment focus
Exhibit 66: Merck & Co., Inc. - Key offerings
Exhibit 67: Merck & Co., Inc. - Key customers
Exhibit 68: Novartis AG - Vendor overview
Exhibit 69: Novartis AG - Business segments
Exhibit 70: Novartis AG - Organizational developments
Exhibit 71: Novartis AG - Geographic focus
Exhibit 72: Novartis AG - Segment focus
Exhibit 73: Novartis AG - Key offerings
Exhibit 74: Novartis AG - Key customers
Exhibit 75: Shenzhen Chipscreen Biosciences Co., Ltd. - Vendor overview
Exhibit 76: Shenzhen Chipscreen Biosciences Co., Ltd. - Organizational developments
Exhibit 77: Shenzhen Chipscreen Biosciences Co., Ltd. - Key offerings
Exhibit 78: Shenzhen Chipscreen Biosciences Co., Ltd. - Key customers
Exhibit 79: Spectrum Pharmaceuticals, Inc. - Vendor overview
Exhibit 80: Spectrum Pharmaceuticals, Inc. - Business segments
Exhibit 81: Spectrum Pharmaceuticals, Inc. - Organizational developments
Exhibit 82: Spectrum Pharmaceuticals, Inc. - Geographic focus
Exhibit 83: Spectrum Pharmaceuticals, Inc. - Key offerings
Exhibit 84: Spectrum Pharmaceuticals, Inc. - Key customers
Exhibit 85: Validation techniques employed for market sizing
Keyplayers in Global HDAC (histone deacetylase) Inhibitors Market 2019-2023
CELGENE CORPORATIONMerck & Co., Inc.
Novartis AG
Shenzhen Chipscreen Biosciences Co., Ltd.
Spectrum Pharmaceuticals, Inc.